TALi is one of only a handful digital therapeutics technologies showcased with evidence based and in-market solutions recognised by global regulators.
TALi Digital Ltd (ASX: TD1, “TALi” or “the Company”), a leading global digital health business is pleased to update the market on the showcase of TALi in the Digital Therapeutics Alliance (DTA) product library. Access to the showcase can be found here: https://dtxalliance.org/understanding-dtx/product-library/ These types of initiatives are undertaken by the DTA “To help key stakeholders understand and differentiate digital therapeutics from the thousands of other mobile health apps that are available, DTA developed this library to highlight evidence-based innovative digital therapeutics (DTx) products.
The products in this library are currently in-market and meet the definition of a DTx product and attest to aligning with industry Core Principles”. TALi has also been accepted as a member of the DTA. Managing Director and CEO of TALi, Mr. Glenn Smith remarked, “TALi is pleased to join this preeminent global organisation where members are regarded as industry thought leaders in healthcare worldwide.
The showcase of TALi combined with our membership of the DTA will only serve to assist our goal of executing additional partnerships in various jurisdictions to ensure the commercialisation success for TALi”. Members of the DTA may be found here: https://dtxalliance.org/join-dta/ Founded in 2017, the Digital Therapeutics Alliance is a 501(c)(6) non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of DTx.
As the leading international organization on digital therapeutic thought leadership and education, the Digital Therapeutics Alliance provides patients, clinicians, payors, and policymakers with the necessary tools to evaluate and utilize DTx products.